Role of bone and kidney in tumor-induced hypercalcemia and its treatment with bisphosphonate and sodium chloride
- 1 June 1987
- journal article
- research article
- Published by Elsevier in American Journal Of Medicine
- Vol. 82 (6), 1133-1142
- https://doi.org/10.1016/0002-9343(87)90215-4
Abstract
No abstract availableThis publication has 29 references indexed in Scilit:
- COMPARISON OF AMINOHYDROXYPROPYLIDENE DIPHOSPHONATE, MITHRAMYCIN, AND CORTICOSTEROIDSICALCITONIN IN TREATMENT OF CANCER-ASSOCIATED HYPERCALCAEMIAThe Lancet, 1985
- Treatment of malignant hypercalcaemia with clodronateBritish Journal of Cancer, 1985
- COMPARISON OF INTRAVENOUS (3-AMINO-1-HYDROXYPROPYLIDENE)-1, 1-BISPHOSPHONATE AND VOLUME REPLETION IN TUMOUR-INDUCED HYPERCALCAEMIAThe Lancet, 1983
- The use of dichloromethylene diphosphonate for the management of hypercalcaemia in multiple myelomaBritish Journal of Haematology, 1983
- Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: Observations on regulation of serum calciumCalcified Tissue International, 1982
- Comparison of two parenteral diphosphonates in hypercalcemia of malignancyThe American Journal of Medicine, 1982
- Effects of disodium dichloromethylene diphosphonate on hypercalcemia produced by bone metastases.Journal of Clinical Investigation, 1980
- DiphosphonatesCalcified Tissue International, 1979
- INHIBITION OF OSTEOLYTIC BONE LESIONS BY (3-AMINO-1-HYDROXYPROPYLIDENE)-1, 1-BISPHOSPHONATE (A.P.D.)The Lancet, 1979
- Hypercalcemic NephropathyArchives of Internal Medicine, 1978